Lipocine To Present 52 Week Results From LPCN 1148 Phase 2 Study In Late Breaking Session At EASL Congress 2024

6/10/24 8:02:02 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LPCN alert in real time by email

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company, today announced that Phase 2 results on LPCN 1148 in cirrhosis were featured in a late breaking oral presentation at the European Association for the Study of Liver (EASL) Congress on Saturday, June 8, in Milan, Italy. The presentation "Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy (HE) in patients with cirrhosis: a 52-week phase 2 randomized clinical trial" was presented by Arun J. Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University. The presentation is featured in the symposium "Revolutionary Advances in Liver Disease Research Unveiled at EASL Congress 2024" (https://www.hepmag.com/article/revolutionary-advances-liver-disease-research-unveiled-easl-congress-2024) highlighting significant advances in liver disease.

Get the next $LPCN alert in real time by email

Date	Price Target	Rating	Analyst
8/26/2021	$2.50 → $3.50	Buy	HC Wainwright & Co.
6/24/2021	$3.00	Overweight	Cantor Fitzgerald

Lipocine To Present 52 Week Results From LPCN 1148 Phase 2 Study In Late Breaking Session At EASL Congress 2024

Chat with this insight

Recent Analyst Ratings for $LPCN

$LPCN SEC Filings

SEC Form 8-K filed by Lipocine Inc.

SEC Form 10-Q filed by Lipocine Inc.

Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$LPCN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Papapetropoulos Spyros

SEC Form 4 filed by Ono Richard Dana

SEC Form 4 filed by Jene Jill M.

$LPCN Leadership Updates

Live Leadership Updates

LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS

$LPCN Market Insights

Live Market Insights

Lipocine Says LPCN 1154 Met standard Bioequivalence (BE) Criteria; Co Says On Track For NDA Filing, Targeting Q4 2024

12 Health Care Stocks Moving In Wednesday's Intraday Session

Lipocine To Present 52 Week Results From LPCN 1148 Phase 2 Study In Late Breaking Session At EASL Congress 2024

$LPCN Press Releases

Fastest customizable press release news feed in the world

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

$LPCN Financials

Live finance-specific insights

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

$LPCN Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Lipocine Inc. (Amendment)

SEC Form SC 13G/A filed

SEC Form SC 13G filed

$LPCN FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for TESTOSTERONE UNDECANOATE issued to LIPOCINE INC

FDA Tentative Approval for TESTOSTERONE UNDECANOATE

$LPCN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on Lipocine with a new price target

Cantor Fitzgerald initiated coverage on Lipocine with a new price target

HC Wainwright & Co. reiterated coverage on Lipocine with a new price target

Recent Analyst Ratings for
$LPCN

$LPCN
SEC Filings

$LPCN
Insider Trading

$LPCN
Leadership Updates

$LPCN
Market Insights

$LPCN
Press Releases

$LPCN
Financials

$LPCN
Large Ownership Changes

$LPCN
FDA approvals

$LPCN
Analyst Ratings